Campbell & Co Investment Adviser’s AbbVie ABBV Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,436	Closed	-$2.84M	–	1016
2025 Q4	$2.84M	Buy	12,436 +6,956	+127%	+$1.58M	0.14%	226
2025 Q3	$1.27M	Buy	+5,480	New	+$1.12M	0.1%	331
2025 Q2	–	Sell	-34,587	Closed	-$7.25M	–	1105
2025 Q1	$7.25M	Buy	+34,587	New	+$6.72M	0.56%	8
2024 Q4	–	Sell	-7,804	Closed	-$1.54M	–	1020
2024 Q3	$1.54M	Buy	+7,804	New	+$1.46M	0.11%	270
2024 Q1	–	Sell	-1,512	Closed	-$234K	–	1069
2023 Q4	$234K	Buy	+1,512	New	+$220K	0.02%	1000
2020 Q3	–	Sell	-4,308	Closed	-$423K	–	370
2020 Q2	$423K	Buy	+4,308	New	+$379K	0.54%	40
2019 Q4	–	Sell	-3,861	Closed	-$292K	–	627
2019 Q3	$292K	Buy	3,861 +847	+28%	+$58.1K	0.11%	398
2019 Q2	$219K	Sell	3,014 -649	-18%	-$51K	0.1%	430
2019 Q1	$295K	Buy	+3,663	New	+$300K	0.15%	280
2018 Q1	–	Sell	-4,181	Closed	-$404K	–	345
2017 Q4	$404K	Buy	4,181 +1,888	+82%	+$178K	0.3%	103
2017 Q3	$204K	Buy	+2,293	New	+$175K	0.16%	290

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Campbell & Co Investment Adviser's ABBV Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 12,436 shares — an estimated $2.84M sold.

Campbell & Co Investment Adviser first reported a position in ABBV in Q3 2017 and held it in 11 quarters. The position peaked at $7.25M in Q1 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Campbell & Co Investment Adviser reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Campbell & Co Investment Adviser sold 12,436 AbbVie shares in Q1 2026, an estimated $2.84M.
Campbell & Co Investment Adviser first reported a position in AbbVie in Q3 2017 and held it in 11 quarters.
Campbell & Co Investment Adviser's AbbVie position peaked at $7.25M in Q1 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.